To determine whether and how Mediator kinase disruption due to pathogenic mutations in MED12 programs MM SCs to acquire the UF phenotype, we profiled the transcriptomic and epigenomic changes induced by pharmacologic inhibition of CDK8/19 in patient-derived MM SCs. This evidence concerns the gene MED12 and Miyoshi myopathy.